These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 10917389)

  • 1. Relationship between clinical and biologic variables and chloramphenicol pharmacokinetic parameters in pediatric patients with sepsis.
    Lugo Goytia G; Lares-Asseff I; Pérez Guillé MG; Pérez AG; Mejía CL
    Ann Pharmacother; 2000 Mar; 34(3):393-7. PubMed ID: 10917389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis.
    Lugo-Goytia G; Castañeda-Hernández G
    Ann Pharmacother; 2000 Dec; 34(12):1389-94. PubMed ID: 11144694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bayesian prediction of chloramphenicol blood levels in children with sepsis and malnutrition].
    Lares-Asseff I; Lugo-Goytia G; Pérez-Guillé MG; Pérez Ortíz B; Guillé-Pérez A; Juárez-Olguín H; Flores-Pérez J; Santiago P; Morlán M
    Rev Invest Clin; 1999; 51(3):159-65. PubMed ID: 10466006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of gentamicin in horses.
    Martín-Jiménez T; Papich MG; Riviere JE
    Am J Vet Res; 1998 Dec; 59(12):1589-98. PubMed ID: 9858412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates.
    Lanao JM; Calvo MV; Mesa JA; Martín-Suárez A; Carbajosa MT; Miguelez F; Domínguez-Gil A
    J Antimicrob Chemother; 2004 Jul; 54(1):193-8. PubMed ID: 15150171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
    Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
    J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis.
    Lugo G; Castañeda-Hernández G
    Ther Drug Monit; 1997 Jun; 19(3):271-6. PubMed ID: 9200766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cefuroxime Bayesian pharmacokinetics in severely ill septic children].
    Lares-Asseff I; Lugo-Goytía G; Pérez-Guillé MG; Flores-Pérez J; Juárez-Olguín H; Raquel Moreno MA
    Rev Invest Clin; 1998; 50(4):311-6. PubMed ID: 9830319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
    Carlsson KC; Hoem NO; Glauser T; Vinks AA
    Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic parameters of vancomycin in critically ill patients.
    Llopis-Salvia P; Jiménez-Torres NV
    J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive performance of a vancomycin-aminoglycoside population model.
    Beringer PM; Wong-Beringer A; Rho JP
    Ann Pharmacother; 1998 Feb; 32(2):176-81. PubMed ID: 9496400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of sepsis upon gentamicin pharmacokinetics in neonates.
    Lingvall M; Reith D; Broadbent R
    Br J Clin Pharmacol; 2005 Jan; 59(1):54-61. PubMed ID: 15606440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.